Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers

Eltahir, Heba M.; Nazmy, Maiiada Hassan

doi:10.1016/j.biopha.2017.11.028

Cited by 25 publications

(19 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our in vivo studies in an animal models exposed to chemotherapeutic drug (bleomycin) or radiation; stimuli known to induce fibrosis (ECM deposition), also showed that administration of the PPI esomeprazole significantly reduced collagen accumulation in the lungs and skin (20,21). Other studies also reported that PPIs reduce collagen accumulation in the liver (22). Intriguingly, there is also a report that lung fibrosis patients who happened to be on PPIs had reduced fibrosis score on high resolution computed tomography (HRCT) scans (23) suggesting that PPIs might target collagen.…”

Section: Perspectivesupporting

confidence: 72%

Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?

Ghebre

2020

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

Section: Perspectivesupporting

confidence: 72%

Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?

Ghebre

2020

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…However, comparison of the antioxidant activity of the drugs that belong to this class has not been reported yet. Also, the previous reports focussed on the antioxidant activity of the active protonated forms of individual PPIs [21, 22]. In this study, the reaction medium only included water and methanol, and as is known, activation of PPIs occurs only in acidic medium (including the stomach); therefore, in agreement with a previous report, the present study revealed that the antioxidant effect of the PPIs can be mediated by the parent drugs, and conversion of these drugs to their protonated form retains their antioxidant activity [23].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole

et al. 2020

View full text Add to dashboard Cite

Introduction: Peptic lesions usually develop when there is an imbalance between aggressive drivers and gastro-protective mediators that guard the lining of the gastrointestinal tract. The most crucial of these mediators are antioxidants, whose loss may predispose to oxidative stress, which is believed to be the main aggravator of several diseases including peptic ulcer. Proton pump inhibitors (PPIs) are drugs that are highly effective and widely used for therapeutic management of peptic disorders through inhibition of gastric acid secretion. In spite of this, oxidative damage may continue to be a major issue that can predispose to future lesions. Objective: The present study is designed to explore the possible antioxidant capability of different PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, in an aim to suggest an agent that, in addition to its acid-suppression properties, can provide antioxidant profit. Methods: The antioxidant activity of different PPIs was evaluated calorimetrically to test the ability of each drug to quench oxygen free radical, using the well-known stable free radical α,α-diphenyl-β-picrylhydrazyl (DPPH), and compared to ascorbic acid (AA; vitamin C). The measurements were performed using a spectrophotometer at 517 nm. Results: All the studied drugs reduced DPPH, but to different extents. However, omeprazole and esomeprazole showed the highest ability to scavenge free radicals (50% inhibitory concentrations [IC 50 s] of the percentage for free radical scavenging activity are 18.7 ± 5.7 and 18.7 ± 5.7, respectively, and the AA equivalents are 83,772 ± 11,887 and 81,732 ± 8,523 mg AA/100 g, respectively). Conversely, lansoprazole, pantoprazole, and rabeprazole might be having no role in this story (IC 50 s of the percentage for free radical scavenging activity are 49.3 ± 3.1, 49 ± 9.4, and 40.7 ± 7.2, respectively, and the AA equivalents are 30,458 ± 3,884, 32,222 ± 10,377, and 37,876 ± 8,816 mg AA/100 g, respectively). Conclusion: Thus, omeprazole and esomeprazole may confer a significant dual action in gastrointestinal protection by providing potent antioxidant properties in addition to their major role as acid-suppression agents. However, further studies are essential to elucidate the mechanism behind the difference between the drugs of the same class.

show abstract

“…Liver fibrosis is a complex dynamic process mediated by the death of hepatocytes and activation of HSCs. The generation of ROS, tumor necrosis factor- α , TGF- β , and PDGF can be implicated as a cause of hepatic fibrosis [33, 34]. The matrix metalloproteinases (MMPs) family is a major group of enzymes responsible for extracellular matrix (ECM) degradation and their activity is regulated by protein inhibitors called TIMPs [35].…”

Section: Discussionmentioning

confidence: 99%

Gallic Acid Attenuates Dimethylnitrosamine-Induced Liver Fibrosis by Alteration of Smad Phosphoisoform Signaling in Rats

Chen

Zhou

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Dimethylnitrosamine (DMN) is a potent hepatotoxin, carcinogen, and mutagen. In our previous study, a candidate gallic acid (GA) that widely exists in food and fruit was selected for its capability to alleviate DMN toxicity in vivo. We aimed to investigate the therapeutic potential of GA against DMN-induced liver fibrosis. During the first four weeks, DMN was administered to rats via intraperitoneal injection every other day, except the control group. GA or silymarin was given to rats by gavage once daily from the second to the sixth week. GA significantly reduced liver damage in serum parameters and improved the antioxidant capacity in liver and kidney tissues. Cytokines involved in liver fibrosis were measured at transcriptional and translational levels. These results indicate that GA exhibits robust antioxidant and antifibrosis effects and may be an effective candidate natural medicine for liver fibrosis treatment.

show abstract

Esomeprazole ameliorates CCl4 induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers

Cited by 25 publications

References 50 publications

Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?

Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target?

Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole

Gallic Acid Attenuates Dimethylnitrosamine-Induced Liver Fibrosis by Alteration of Smad Phosphoisoform Signaling in Rats

Contact Info

Product

Resources

About